IL18BP and macrophage activation syndrome: Patients with mutations in the NLRC4 inflammasome leading to MAS treated with recombinant IL-18BP (Tadekinig alfa) display an alleviation in MAS symptoms and a drastic reduction in circulating cytokines and ferritin [68] with further phase III clinical trials underway (Clinicaltrials.gov Identifier: NCT03113760).